Editas Medicine Intrinsic Value Calculator – EDITAS MEDICINE Bolsters Leadership Team with Appointment of Chair and Director
April 14, 2023
Trending News 🌥️
Editas Medicine ($NASDAQ:EDIT), a leading genome editing company, has made a move to reinforce its leadership team with the appointment of a new Chair and Director. Editas Medicine is a publicly traded company that harnesses the power of genome editing to develop transformative therapies for people living with serious diseases. The company’s proprietary platform, EDITAS Medicine EngineTM, enables the design and delivery of precise genetic medicines to treat a wide range of diseases at the molecular level. In addition to its clinical programs, Editas Medicine is also pursuing research collaborations with leading biopharmaceutical companies and institutions to explore the potential of its platform in various therapeutic areas.
The appointment of Fowler and Walmsley serves to bolster Editas Medicine’s leadership team as it continues its pioneering work in the field of genome editing. Both bring a wealth of knowledge and expertise in the biopharmaceutical industry and will be instrumental in driving the company’s mission forward. With their guidance, Editas Medicine is poised to make even greater strides in developing treatments for patients suffering from serious diseases.
Share Price
On Thursday, EDITAS MEDICINE, a biotechnology company focused on transforming the treatment of serious diseases through the use of CRISPR-based genome editing technology, bolstered its leadership team with the appointment of a Chair and Director. This news sent EDITAS MEDICINE stock soaring, opening at $6.4 and closing at $7.6, a 20.3% increase from the previous day’s closing price. This appointment is seen as a positive sign of future growth potential for the company and its investors. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Editas Medicine. More…
| Total Revenues | Net Income | Net Margin |
| 19.71 | -220.43 | -1118.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Editas Medicine. More…
| Operations | Investing | Financing |
| -177.35 | 114.07 | 1.28 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Editas Medicine. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 514.32 | 153.64 | 5.24 |
Key Ratios Snapshot
Some of the financial key ratios for Editas Medicine are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -1.3% | – | -1146.3% |
| FCF Margin | ROE | ROA |
| -920.6% | -36.4% | -27.5% |
Analysis – Editas Medicine Intrinsic Value Calculator
At GoodWhale, we have analyzed the fundamentals of EDITAS MEDICINE to determine a fair value for its stock. After carefully scrutinizing the company’s financials, our proprietary Valuation Line determined that the fair value of an EDITAS MEDICINE share is $19.2. However, currently EDITAS MEDICINE stock is trading at $7.6, meaning it’s undervalued by 60.4%. This presents a great opportunity for savvy investors to capitalize on this discrepancy. More…
Peers
In the world of gene-editing, three companies have emerged as leaders in the race to develop CRISPR-based treatments: Editas Medicine Inc, Intellia Therapeutics Inc, and CRISPR Therapeutics AG. All three companies are working on treatments for a variety of diseases, ranging from cancer to blindness. However, only Editas has begun to clinical trials on humans. This gives them a significant advantage over their competitors. While all three companies are working on cutting-edge science, Editas is in the lead to bring these treatments to market.
– Intellia Therapeutics Inc ($NASDAQ:NTLA)
Intellia Therapeutics Inc is a genomic editing company. Its technology involves the use of meganucleases and CRISPR/Cas9 to edit genomes. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
As of 2022, Intellia Therapeutics Inc has a market cap of 4.19B and a Return on Equity of -43.06%. The company’s technology involves the use of meganucleases and CRISPR/Cas9 to edit genomes. Intellia Therapeutics Inc was founded in 2014 and is headquartered in Cambridge, Massachusetts.
– CRISPR Therapeutics AG ($NASDAQ:CRSP)
CRISPR Therapeutics AG is a clinical-stage biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases. Its proprietary CRISPR/Cas9 platform enables it to target and edit genes with precision. The company is advancing a broad portfolio of first-in-class gene-edited therapies in hemoglobinopathies, oncology, and rare diseases.
– Beam Therapeutics Inc ($NASDAQ:BEAM)
Beam Therapeutics Inc is a clinical-stage biotechnology company. The Company focuses on developing precision genetic medicines through its proprietary base editing technology. Its product candidates include BTX-A51, BTX-A52, BTX-B18, BTX-B19 and BTX-B20. The Company’s base editor technology enables it to make precise, predictable and permanent changes to single base nucleotides in genomic DNA without making double-stranded breaks or requiring a donor template.
Summary
EDITAS Medicine Inc. (Nasdaq: EDIT) recently appointed a new chairman and director to its board, leading to a stock price increase the same day. Investors may find this development attractive due to the new perspectives and insights that the two appointments bring. The company is focused on the development of transformative gene editing treatments, and has potential in the long-term growth of the gene editing market.
Analysts suggest that EDIT is looking to expand its pipeline and strengthen its presence in the pharmaceuticals industry. With its long-term potential, investors should continue to monitor developments with EDITAS Medicine to uncover potential opportunities.
